Literature DB >> 11530814

Lethal adenovirus infection in a patient who had undergone nonmyeloablative stem cell transplantation.

K Ikegame1, T Takimoto, R Takahashi, M Murakami, H Tamaki, T Fujioka, M Kawakami, N Hirabayashi, T Soma, H Sugiyama, H Ogawa.   

Abstract

We present a case of adenovirus (ADV) infection in a patient who had undergone nonmyeloablative stem cell transplantation (NST). A 50-year-old man with chronic myelogenous leukemia in the second chronic phase underwent NST from an HLA 2-loci-mismatched sibling. ADV hemorrhagic cystitis developed and progressed to lethal pneumonia. ADV was isolated from urine, bronchoalveolar lavage fluid, and postmortem specimens of kidney and liver. Because there are few reports of lethal pneumonia associated with ADV in Japan, we present the case and discuss the cause of and therapy for the infection.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11530814     DOI： 10.1007/BF02982557

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  12 in total

1.  Necrotizing tubulointerstitial nephritis associated with adenovirus infection.

Authors:  M Ito; N Hirabayashi; Y Uno; A Nakayama; J Asai
Journal:  Hum Pathol       Date:  1991-12       Impact factor: 3.466

Review 2.  Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors.

Authors:  C Anasetti; J A Hansen
Journal:  Transfus Sci       Date:  1994-09

3.  Respiratory viral infections in lung transplant recipients: radiologic findings with clinical correlation.

Authors:  L D Matar; H P McAdams; S M Palmer; D N Howell; N G Henshaw; R D Davis; V F Tapson
Journal:  Radiology       Date:  1999-12       Impact factor: 11.105

4.  Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation.

Authors:  R Hromas; K Cornetta; E Srour; C Blanke; E R Broun
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

5.  WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.

Authors:  K Inoue; H Sugiyama; H Ogawa; M Nakagawa; T Yamagami; H Miwa; K Kita; A Hiraoka; T Masaoka; K Nasu
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

6.  Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors.

Authors:  K Miyamura; M Hamaguchi; H Taji; T Kanie; A Kohno; M Tanimoto; H Saito; S Kojima; T Matsuyama; K Kitaori; K Nagafuji; T Sato; Y Kodera
Journal:  Bone Marrow Transplant       Date:  2000-03       Impact factor: 5.483

7.  Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins.

Authors:  L Genestier; S Fournel; M Flacher; O Assossou; J P Revillard; N Bonnefoy-Berard
Journal:  Blood       Date:  1998-04-01       Impact factor: 22.113

8.  Adenovirus pneumonia in lung transplant recipients.

Authors:  N P Ohori; M G Michaels; R Jaffe; P Williams; S A Yousem
Journal:  Hum Pathol       Date:  1995-10       Impact factor: 3.466

9.  Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation.

Authors:  H Einsele; G Ehninger; M Steidle; I Fischer; S Bihler; F Gerneth; A Vallbracht; H Schmidt; H D Waller; C A Müller
Journal:  Blood       Date:  1993-09-01       Impact factor: 22.113

10.  Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation.

Authors:  H Gondo; T Minematsu; M Harada; K Akashi; S Hayashi; S Taniguchi; K Yamasaki; T Shibuya; Y Takamatsu; T Teshima
Journal:  Br J Haematol       Date:  1994-01       Impact factor: 6.998
View more
  1 in total

1.  Adenovirus diseases: a systematic review and meta-analysis of 228 case reports.

Authors:  Jie Gu; Qing-Qing Su; Ting-Ting Zuo; Yan-Bin Chen
Journal:  Infection       Date:  2020-07-27       Impact factor: 7.455
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.